NasdaqGM - Delayed Quote USD

Castle Biosciences, Inc. (CSTL)

19.86 -0.20 (-1.00%)
At close: April 24 at 4:00 PM EDT
19.86 0.00 (0.00%)
After hours: April 24 at 4:02 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Derek J. Maetzold Founder, CEO, President & Director 1.61M -- 1962
Mr. Frank Stokes CFO & Treasurer 880.25k 75.52k 1971
Ms. Kristen M. Oelschlager R.N. Chief Operating Officer 828.48k 234.2k 1968
Mr. Tobin W. Juvenal Chief Commercial Officer 829.1k 126.36k 1960
Camilla Zuckero Vice President of Investor Relations & Corporate Affairs -- -- --
Ms. Alice Bahner Izzo Senior Vice President of Marketing -- -- --
Mr. Kevin Doman Vice President of Sales -- -- --
Ms. Keli Greenberg VP of Human Resources & Executive Director of Human Resources -- -- --
Dr. Robert W. Cook Ph.D. Senior Vice President of Research & Development -- -- 1972
Dr. Matthew Goldberg M.D. Senior Vice President of Medical -- -- --

Castle Biosciences, Inc.

505 South Friendswood Drive
Suite 401
Friendswood, TX 77546
United States
866 788 9007 https://castlebiosciences.com
Sector: 
Healthcare
Full Time Employees: 
610

Description

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Corporate Governance

Castle Biosciences, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024
Castle Biosciences, Inc. Earnings Call

Related Tickers

BDSX Biodesix, Inc.
1.2600
-1.56%
 
ECX.F EPIGENOMICS AG NA O.N.
1.5150
+0.33%
 
BCART.BR Biocartis Group NV
0.2900
0.00%
 
DMTK DermTech, Inc.
0.6140
-0.32%
 
CDNA CareDx, Inc
7.98
-3.04%
 
FLGT Fulgent Genetics, Inc.
20.74
+0.48%
 
BNR Burning Rock Biotech Limited
0.8208
-5.29%
 
CNTG Centogene N.V.
0.4610
-3.96%
 
ENZ Enzo Biochem, Inc.
1.0600
-2.75%
 
GH Guardant Health, Inc.
18.10
+4.38%